TAK-632 (TAK 632; TAK632) is a novel and potent pan-Raf inhibitor with potential antineoplastic activity.

PLX4720 (PLX-4720; PLX 4720), a 7-azaindole/pyrrolopyridine-based vemurafenib derivative discovered by a structure-guided discovery approach, is a novel, potent and selective inhibitor of B-RafV600E mutant with potential antitumor activity.

Naporafenib (LXH254; LXH-254), extracted from patent WO2018051306A1, compound A, is a novel, potent and orally bioavailable C-RAF inhibitor with anticancer activity.

LY03009120 (DP4978; LY-3009120; LY-03009120; DP-4978) is a novel and potent pan-Raf inhibitor with potential anticancer activity.

PLX8394 (PLX-8394) is a novel, potent, orally bioavailable and selective inhibitor of the serine/threonine-protein kinase B-raf (BRaf) with anticancer activity.

Encorafenib (formerly LGX818; LGX-818; trade name Braftovi), an approved anticancer drug, is a highly potent, and orally bioavailable B-RAFV600E inhibitor with potential antineoplastic activity.

Dabrafenib mesylate (formerly GSK-2118436 mesylate; Tafinlar), the mesylate salt of dabrafenib, is an orally bioavailable BRAF V600 inhibitor that has been approved in 2013 by FDA to treat melanoma.

GW5074 (GW-5074; GW 5074) is a novel, potent and selective c-Raf inhibitor with potential neuroprotective activity.

Sorafenib (BAY549085; BAY-549085; BAY439006; BAY-439006; Nexavar; SFN), an approved anticancer drug, is a potent and orally bioavailable multikinase inhibitor with potential anticancer activity.

Exarafenib(also known as RAF/KIN-2787),is a novel and potent pan-RAF inhibitor.